Download
s40520-020-01519-x.pdf 746,62KB
WeightNameValue
1000 Titel
  • Safety and tolerability of 6-month supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink in sarcopenic older adults
1000 Autor/in
  1. Mikušová, Lucia |
  2. Garthoff, Jossie A. |
  3. Luiking, Yvette |
  4. Bauer, Jürgen M. |
  5. Verlaan, Sjors |
  6. Bautmans, Ivan |
  7. Brandt, Kirsten |
  8. Donini, Lorenzo M. |
  9. Maggio, Marcello |
  10. McMurdo, Marion E. T. |
  11. Mets, Tony |
  12. Seal, Chris |
  13. Wijers, Sander L. J. |
  14. Ceda, Gian Paolo |
  15. De Vito, Giuseppe |
  16. Donders, Gilbert |
  17. Drey, Michael |
  18. Greig, Carolyn |
  19. Holmbäck, Ulf |
  20. Narici, Marco |
  21. McPhee, Jamie |
  22. Poggiogalle, Eleonora |
  23. Power, Dermot |
  24. Scafoglieri, Aldo |
  25. Schultz, Ralf |
  26. Sieber, Cornel |
  27. Cederholm, Tommy |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-03-12
1000 Erschienen in
1000 Quellenangabe
  • 32(8):1501-1514
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40520-020-01519-x |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7452877/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Aims!#!Safety and tolerability of prolonged supplementation with a vitamin D, calcium and leucine-enriched whey protein medical nutrition drink (WP-MND) was evaluated in sarcopenic older adults.!##!Methods!#!A 13-week double-blinded, randomized, isocaloric placebo-controlled trial (PROVIDE study; n = 380) was extended with a voluntary 13-week open-label extension (OLE). OLE participants were randomized to receive daily 1 or 2 servings of WP-MND (21 g protein, 3 g leucine, 10 µg vitD and 500 mg calcium per serving). Gastro-intestinal tolerability, kidney function and serum levels of calcidiol, parathyroid hormone (PTH) and calcium were evaluated at week 0, 13 and 26.!##!Results and discussion!#!In response to the high daily protein intake (median1.5; IQR: 1.3, 1.7 g/kg BW/day), the estimated glomerular filtration rate (eGFR) increased in the test group during the RCT (p = 0.013). The same trend was observed for those participants with moderate chronic kidney disease. During OLE no eGFR change was observed in any of the groups. Serum calcidiol and calcium reached a plateau after 13-week WP-MND supplementation. As expected, PTH significantly changed in the opposite direction, decreasing during RCT in the test group (T vs C: p < 0.001) and during OLE in former control groups. During RCT, 20/366 participants with normal baseline calcidiol reached levels ≥ 100 nmol/L (T: n = 18; C: n = 2) and 6 developed albumin-corrected calcium levels > 2.55 mmol/L (T: n = 3; C: n = 3), without associated adverse events.!##!Conclusion!#!A 6 months intervention with up to 2 servings of WP-MND did neither result in kidney function deterioration nor symptoms of vitamin D or calcium toxicity. The product was overall well tolerated.
1000 Sacherschließung
lokal Whey Proteins/adverse effects [MeSH]
lokal Double-Blind Method [MeSH]
lokal Female [MeSH]
lokal Nutrition
lokal Aged [MeSH]
lokal Humans [MeSH]
lokal Sarcopenia/diet therapy [MeSH]
lokal Whey protein
lokal Safety
lokal Vitamin D [MeSH]
lokal Original Article
lokal Male [MeSH]
lokal Dietary Supplements [MeSH]
lokal Leucine/adverse effects [MeSH]
lokal Sarcopenia
lokal Vitamin D
lokal Calcium [MeSH]
lokal Tolerability
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/TWlrdcWhb3bDoSwgTHVjaWE=|https://frl.publisso.de/adhoc/uri/R2FydGhvZmYsIEpvc3NpZSBBLg==|https://frl.publisso.de/adhoc/uri/THVpa2luZywgWXZldHRl|https://frl.publisso.de/adhoc/uri/QmF1ZXIsIErDvHJnZW4gTS4=|https://frl.publisso.de/adhoc/uri/VmVybGFhbiwgU2pvcnM=|https://frl.publisso.de/adhoc/uri/QmF1dG1hbnMsIEl2YW4=|https://frl.publisso.de/adhoc/uri/QnJhbmR0LCBLaXJzdGVu|https://frl.publisso.de/adhoc/uri/RG9uaW5pLCBMb3JlbnpvIE0u|https://frl.publisso.de/adhoc/uri/TWFnZ2lvLCBNYXJjZWxsbw==|https://frl.publisso.de/adhoc/uri/TWNNdXJkbywgTWFyaW9uIEUuIFQu|https://frl.publisso.de/adhoc/uri/TWV0cywgVG9ueQ==|https://frl.publisso.de/adhoc/uri/U2VhbCwgQ2hyaXM=|https://frl.publisso.de/adhoc/uri/V2lqZXJzLCBTYW5kZXIgTC4gSi4=|https://frl.publisso.de/adhoc/uri/Q2VkYSwgR2lhbiBQYW9sbw==|https://frl.publisso.de/adhoc/uri/RGUgVml0bywgR2l1c2VwcGU=|https://frl.publisso.de/adhoc/uri/RG9uZGVycywgR2lsYmVydA==|https://frl.publisso.de/adhoc/uri/RHJleSwgTWljaGFlbA==|https://frl.publisso.de/adhoc/uri/R3JlaWcsIENhcm9seW4=|https://frl.publisso.de/adhoc/uri/SG9sbWLDpGNrLCBVbGY=|https://frl.publisso.de/adhoc/uri/TmFyaWNpLCBNYXJjbw==|https://frl.publisso.de/adhoc/uri/TWNQaGVlLCBKYW1pZQ==|https://frl.publisso.de/adhoc/uri/UG9nZ2lvZ2FsbGUsIEVsZW9ub3Jh|https://frl.publisso.de/adhoc/uri/UG93ZXIsIERlcm1vdA==|https://frl.publisso.de/adhoc/uri/U2NhZm9nbGllcmksIEFsZG8=|https://frl.publisso.de/adhoc/uri/U2NodWx0eiwgUmFsZg==|https://frl.publisso.de/adhoc/uri/U2llYmVyLCBDb3JuZWw=|https://frl.publisso.de/adhoc/uri/Q2VkZXJob2xtLCBUb21teQ==
1000 Hinweis
  • DeepGreen-ID: 1d1df7fd6e8a4f248792dd89834d435f ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6471830.rdf
1000 Erstellt am 2023-11-18T16:05:31.673+0100
1000 Erstellt von 322
1000 beschreibt frl:6471830
1000 Zuletzt bearbeitet 2024-04-05T10:52:06.637+0200
1000 Objekt bearb. Fri Apr 05 10:52:06 CEST 2024
1000 Vgl. frl:6471830
1000 Oai Id
  1. oai:frl.publisso.de:frl:6471830 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source